As the Democratic Republic of the Congo faces its fastest-growing Ebola outbreak on record, GeoVax Labs, Inc. (Nasdaq: GOVX) is drawing attention to its extensive experience in developing vaccines against hemorrhagic fever viruses. The outbreak, caused by the Bundibugyo virus (BDBV), has already resulted in more than 4,300 cases and 2,000 deaths, according to the World Health Organization (WHO). With no approved vaccine specifically targeting BDBV, the need for effective countermeasures is urgent.
GeoVax, a biotechnology company focused on infectious diseases and cancers, has leveraged its Modified Vaccinia Ankara (MVA) platform to create vaccine candidates against Zaire ebolavirus, Sudan ebolavirus, and Marburg virus. These candidates have shown encouraging protective efficacy in non-human primate lethal-challenge studies. The company is now signaling its readiness to contribute to the global response, offering its scientific expertise, vaccine candidates, and materials for evaluation against the Bundibugyo virus.
David Dodd, Chairman and CEO of GeoVax, emphasized the importance of preparedness: "The rapidly escalating Ebola Bundibugyo outbreak underscores the importance of having vaccine technologies and capabilities available before a crisis occurs. We are prepared to engage with WHO, Africa CDC, national public health authorities, and other appropriate organizations to determine whether our vaccine candidates, technology, or scientific expertise could contribute to the response."
GeoVax's lead infectious disease program, GEO-MVA, remains its primary focus. This MVA-based vaccine is being developed for the prevention of mpox and smallpox, with a pivotal clinical program planned using an immunobridging accelerated regulatory pathway. A portion of this program is expected to be conducted in African regions, including areas affected by the current Ebola outbreak. The company is already building relationships with healthcare and research organizations in the region, which could facilitate collaboration on Ebola response efforts.
"Our relationships in the region are being developed first and foremost to advance GEO-MVA, but many of the organizations with whom we are engaging are simultaneously confronting this Ebola outbreak," Dodd added. "Given our experience, we believe it is appropriate to ask how we might help. Any such effort would be pursued collaboratively while maintaining our operational and capital focus on GEO-MVA."
Beyond GEO-MVA, GeoVax retains a portfolio of MVA-based hemorrhagic fever vaccine candidates that have demonstrated protective efficacy in animal models. These programs represent strategic optionality, and the company is open to discussing collaborations, licensing arrangements, and public-private partnerships that could provide resources for further development without diverting attention from its primary program.
The company's combination of MVA platform expertise, vaccine candidates, and work on scalable MVA manufacturing positions it as a potential partner in addressing Ebola and other emerging infectious disease threats. GeoVax's broader strategy includes innovations such as a continuous cell-line manufacturing process, potential single-dose regimens, and microarray patch delivery, all aimed at improving the accessibility and scalability of MVA vaccines.
As the world watches the Congo outbreak with concern, GeoVax's proactive stance highlights the importance of having versatile vaccine platforms ready to respond to evolving public health crises. The company's willingness to contribute its resources and knowledge could play a role in mitigating the impact of this devastating outbreak.
